Exelixis (EXEL) Tops Q1 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Exelixis (EXEL) Tops Q1 EPS by 21c

Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update

May 2, 2018 4:05 PM EDT

- Total Revenues of $212.3 million -

- Cabozantinib Franchise Net Product Revenues of $134.3 million -

- Net Income of $115.9 million, Diluted EPS of $0.37 -

- Conference Call and Webcast Today at 5:00 PM Eastern Time -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

... More